2024-08-31-世界卫生组织-EYE_Annual_highlights_2023,_French_7页_978kb

EYE Strategy 2023 Summary

Key Statistics and Overview

• Yellow fever cases and epidemics in Africa and Americas since 2016.
• Vaccination campaigns initiated in 2017; by 2023, over 62 million people vaccinated.
• 4106 cases reported; data indicates increasing risks despite interventions.
• Graph shows epidemics rising from 2017 to 2023, with higher frequency in high-risk zones.

Vaccination Achievements

• Countries protected populations through campaigns:
  • Niger: ~221,000 people via RVC.
  • Nigeria: ~18.7 million in preventive campaigns.
  • Ouganda: ~9.5 million in multi-year efforts.
  • Other countries in Africa contributed significantly.
  • Americas: ~184,454 doses administered, including in Belize, Guyana, and Panama.

Regional Activities

• Africa:
  • Technical support in Guinea, Central African Republic, DR Congo, and Tchad.
  • Events like the regional meeting in Congo and workshops for risk evaluations.
• Latin America and Caribbean:
  • Vaccination campaigns in countries such as Anguila, Jamaica, Brazil, and others.
  • Online surveys and studies to assess immunity and vaccination practices; data analysis ongoing.
  • Use of tools like PAHO-IRIS profiles for high-risk nations.

Working Groups

• Laboratory Testing:
  • Manual and guides updated; five countries formed or updated labs.
  • 72 sample shipments, average turnaround time 4.7 days.
• Risk Analysis:
  • High-risk countries identified: Nigeria, DR Congo, Cameroon, Ghana, Uganda.
  • Infiranational risk assessments completed to inform vaccine distribution.
• Supply and Vaccines:
  • UNICEF provided millions of doses; Gavi approved funding for diagnostics.
  • Improved tools and evaluation methods for vaccine coverage.
• Secretariat:
  • Mid-term evaluation report published; digital tools developed for epidemic tracking.
  • New analysis tools for immunity gaps in high-risk countries.

Current Risks and Ongoing Efforts

• High-risk areas: Cameroon, Central African Republic, South Sudan, due to immunity gaps.
• Four districts approved for 2023 vaccines; response planning for new outbreaks.
• Plans for 2024 include vaccine allocations and addressing immunity lapses, with risks persisting in endemic zones.